| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1023/A:1008368319526 |
| P698 | PubMed publication ID | 10761748 |
| P50 | author | Isabelle Ray-Coquard | Q37995869 |
| P2093 | author name string | C Ardiet | |
| J P Guastalla | |||
| T Bachelot | |||
| G Catimel | |||
| M Clavel | |||
| F Chauvin | |||
| J P Droz | |||
| T Philip | |||
| A Dumortier | |||
| P2860 | cites work | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project | Q28251216 | ||
| Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149. | Q33489742 | ||
| Responses and toxic deaths in phase I clinical trials | Q37863716 | ||
| Race, nutritional status, and survival from breast cancer | Q44632953 | ||
| A phase I trial on the ethics of phase I trials | Q49177302 | ||
| International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group | Q56474871 | ||
| Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid | Q67549023 | ||
| Response rates, duration of response, and dose response effects in phase I studies of antineoplastics | Q67899179 | ||
| Predicting life span for applicants to inpatient hospice | Q67976523 | ||
| Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients | Q71347104 | ||
| How long have I got doctor? | Q71626397 | ||
| Serum YKL-40: A new potential marker of prognosis and location of métastases of patients with recurrent breast cancer | Q71784066 | ||
| Prognostic factors for survival in patients treated in phase I clinical trials | Q72178801 | ||
| Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group | Q72274218 | ||
| Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors | Q72327079 | ||
| Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors | Q72368992 | ||
| Critical role of phase I clinical trials in cancer treatment. American Society of Clinical Oncology | Q73117425 | ||
| P433 | issue | 2 | |
| P921 | main subject | phase I clinical trial | Q5452194 |
| P304 | page(s) | 151-156 | |
| P577 | publication date | 2000-02-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials | |
| P478 | volume | 11 |
| Q43684447 | "Classical 3 + 3 design" versus "accelerated titration designs": analysis of 270 phase 1 trials investigating anti-cancer agents. |
| Q36093188 | A clinical decision support tool to predict survival in cancer patients beyond 120 days after palliative chemotherapy |
| Q51710026 | A predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic. |
| Q47222469 | Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials |
| Q40368139 | Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials. |
| Q36510136 | Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience |
| Q53577839 | Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience. |
| Q36671063 | Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. |
| Q35917852 | Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database |
| Q43579944 | Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials. |
| Q57571021 | Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics |
| Q87828476 | Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials |
| Q39867384 | Do phase 1 patients have greater needs for palliative care compared with other cancer patients? |
| Q37783623 | Early Oncology Clinical Trial Design in the Era of Molecular-Targeted Agents |
| Q34040965 | Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection? |
| Q36871155 | Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors. |
| Q33600434 | Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer. |
| Q94671629 | First-In-Human Phase 1 Clinical Trials - A Single-Center Experience In The Era Of Modern Oncotherapeutics |
| Q53059034 | Nurse and physician inter-rater agreement of three performance status measures in palliative care outpatients. |
| Q38735014 | Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials |
| Q35584482 | Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic |
| Q36157118 | PRognostic factor of Early Death In phase II Trials or the end of 'sufficient life expectancy' as an inclusion criterion? (PREDIT model). |
| Q34801461 | Participation and survival of geriatric patients in Phase I clinical trials: the Karmanos Cancer Institute (KCI) experience |
| Q92667785 | Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients |
| Q39688507 | Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score |
| Q36288003 | Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin |
| Q85555009 | Pretreatment performance status and nutrition are associated with early mortality of locally advanced head and neck cancer patients undergoing concurrent chemoradiation |
| Q34778981 | Prognosis in advanced cancer |
| Q81343760 | Prognostic factors among cancer patients with good performance status screened for phase I trials |
| Q33371241 | Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review |
| Q41161589 | Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events |
| Q89139059 | Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials |
| Q33399986 | Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience |
| Q30336409 | Safety issues in cell-based intervention trials. |
| Q52594747 | Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience. |
| Q97649707 | Survival and clinical outcomes of patients with ovarian cancer who were treated on phase 1 clinical trials |
| Q34252383 | Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience |
| Q43522124 | Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience |
| Q57471266 | Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials |
| Q73668722 | The prognosis of prognostic factors in phase I clinical trials |
| Q37552648 | The role of age on dose-limiting toxicities in phase I dose-escalation trials |
| Q33846615 | Validation of prognostic scores for survival in cancer patients beyond first-line therapy |
Search more.